Try the modernized beta website. Learn more about the modernization effort.
Working… Menu
Trial record 1 of 1 for:    NCT02501096
Previous Study | Return to List | Next Study

A Trial of Lenvatinib (E7080) Plus Pembrolizumab in Participants With Selected Solid Tumors

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02501096
Recruitment Status : Active, not recruiting
First Posted : July 17, 2015
Last Update Posted : March 7, 2022
Merck Sharp & Dohme LLC
Information provided by (Responsible Party):
Eisai Inc.

No Study Results Posted on for this Study
Recruitment Status : Active, not recruiting
Actual Primary Completion Date : August 18, 2020
Estimated Study Completion Date : June 3, 2022
Certification/Extension First Submitted : June 11, 2021
Publications automatically indexed to this study by Identifier (NCT Number):